You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Position tracking and mobility assessment system for indoor monitoring of elders
SBC: EMBEDRF LLC Topic: NIADESCRIPTION (provided by applicant): The long term objective of this project is to enable elderly persons to independently live within their own homes later into their lives with the assurance that their safety and well-being can be remotely monitored by health care professionals. A critical component of remote health care monitoring is physically tracking the location of the patient within a livi ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Cotton Rat: Animal Model Predictive of Clinical Responses to HSV Vaccines
SBC: VIRION SYSTEMS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Genital herpes is one of the most prevalent sexually transmitted infections worldwide and is associated with substantial morbidity. The impact of genital herpes as a public health threat is amplified because of its epidemiologic synergy with HIV. Epidemiological studies consistently demonstrate that HSV infection increases the risk of HIV transmission and acqu ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
A cost-effective bioreactor to advance functional tissue engineering of cartilage
SBC: Apex Biomedical Company, LLC Topic: NIAMSDESCRIPTION (provided by applicant): Osteoarthritis (OA) is the leading cause of chronic disability in the United States. A clinical goal in the treatment and prevention of OA is to develop replacement cartilage using tissue engineering (TE) technologies. Although TE cartilage presently lacks the mechanical stability of native cartilage, studies have demonstrated that mechanical stability can be e ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Early detection of prostate cancer in urine
SBC: New Horizons Diagnostics Topic: NCIDESCRIPTION (provided by applicant): Prostate cancer is the second most common cancer in men, and the second leading cause of cancer death. However, when prostate cancer is diagnosed in its early stages, it can be effectively treated and cured. Combined with the digital rectal examination, the prostate specific antigen (PSA) test has been widely used to detect prostate cancer in its early stages. ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Novel RTL treatment to promote brain repair and cognitive recovery following meth
SBC: VIROGENOMICS, INC. Topic: NIDADESCRIPTION (provided by applicant): Methamphetamine (MA) dependence is associated with neuropsychiatric side effects that make the addiction extremely challenging to treat. Patients seeking treatment experience ongoing impairments in cognition, mood, and motivation. Currently, there are no FDA-approved pharmacotherapies for MA dependence. The goal of this proof-of-concept research project is test ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Innovative Computer Prototype for HIV Screening and Brief Intervention
SBC: RESEARCH CIRCLE ASSOCIATES Topic: NIDADESCRIPTION (provided by applicant): HIV continues to be a major public health problem in the United States, but there has been limited penetration of HIV prevention services in many healthcare settings. Novel methods for seamlessly integrating HIV prevention into medical practice are needed. The proposed Phase 1 STTR project seeks to establish the feasibility of designing key components of an inn ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Technology Transfer of the ATLAS and ATHENA Programs
SBC: Odyssey Science Innovations, LLC Topic: NIDADESCRIPTION (provided by applicant): Over 7.5 million high school students participate in high school sports programs and an additional 2 million students join these athletic teams each year. Adolescent athletes are at risk for using performance enhancing drugs, such as anabolic steroids, unregulated sport supplements, and illicit drugs and alcohol. Unfortunately, few evidence-based substance abus ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
ApoFasL as a novel treatment for Type 1 Diabetes in Nonhuman Primates
SBC: APOIMMUNE, INC Topic: NIDDKDESCRIPTION (provided by applicant): Pancreatic islet transplantation is a viable approach for the treatment of type 1 diabetes (T1D). However, this therapeutic approach suffers from graft rejection. Dr. Shirwan, founder of ApoImmune, has developed a novel immunotherapeutic approach aimed at tolerance induction to alloantigens without chronic use of general immunosuppression. This approach, terme ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Lentiviral gene therapy for mucopolysaccharidosis
SBC: LENTIGEN CORPORATION Topic: NIDDKDESCRIPTION (provided by applicant): Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an X-linked recessive inherited disorder caused by absence of iduronate-2-sulfatase, resulting in systemic accumulation of glycosaminoglycans heparan sulphate and dermatan sulphate. Affected individuals suffer from skeletal abnormalities, organomegaly, life- threatening obstructive airway disease, and, ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
PROOF OF CONCEPT FOR ANTIMICROBIAL PROPERTIES OF LACRITIN IN VIVO
SBC: EYERX RESEARCH, INC. Topic: NEIDESCRIPTION (provided by applicant): Over the past sixty years, antibiotics have comprised a key component in both the treatment and prophylaxis of bacterial infections. Since that time the continuous development of new antibiotics has been necessary to limit toxicity, promote broader spectrum therapy, increase convenience of use, and decrease the time to clear the infection. Another driving force ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health